Table 2.
Percentages of pertussis seroprevalence and Dt and TT seroprotection per country and by age group.
| IgG-PT (IU/mL) | IgG-Dt (IU/mL) | IgG-TT (IU/mL) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <LLOQ | 50 to <100 | ≥100 | <0.01 | <0.1 | <0.01 | <0.1 | ||||||||||
| Country | Age group | N total | % | % | N | % | a% corr. | N | % | N | % | N | % | N | % | N |
| AT | 40–49 | 250 | 11.2 | 28 | 5.2 | 4.3 | 13 | 10.4 | 26 | 53.6 | 134 | 0.0 | 0 | 1.6 | 4 | |
| 50–59 | 250 | 5.2 | 13 | 3.6 | 2.2 | 9 | 20.0 | 50 | 59.2 | 148 | 0.0 | 0 | 1.6 | 4 | ||
| Total | 500 | 6.0 | 8.2 | 41 | 4.4 | 3.2 | 22 | 15.2 | 76 | 56.4 | 282 | 0.0 | 0 | 1.6 | 8 | |
| BE | 40–49 | 252 | 7.1 | 18 | 7.5 | 7.4 | 19 | 13.5 | 34 | 54.8 | 138 | 0.0 | 0 | 6.0 | 15 | |
| 50–59 | 252 | 11.5 | 29 | 7.1 | 6.8 | 18 | 27.8 | 70 | 63.1 | 159 | 1.2 | 3 | 8.7 | 22 | ||
| Total | 504 | 5.6 | 9.3 | 47 | 7.3 | 7.1 | 37 | 20.6 | 104 | 58.9 | 297 | 0.6 | 3 | 7.3 | 37 | |
| DK | 40–49 | 249 | 7.6 | 19 | 5.6 | 4.9 | 14 | 12.9 | 32 | 52.6 | 131 | 0.4 | 1 | 4.0 | 10 | |
| 50–59 | 242 | 9.5 | 23 | 11.2 | 12.1 | 27 | 15.3 | 37 | 52.9 | 128 | 0.0 | 0 | 5.8 | 14 | ||
| Total | 491 | 4.5 | 8.6 | 42 | 8.4 | 8.4 | 41 | 14.1 | 69 | 52.8 | 259 | 0.2 | 1 | 4.9 | 24 | |
| FI | 40–49 | 250 | 4.0 | 10 | 2.0 | 0.1 | 5 | 3.2 | 8 | 20.4 | 51 | 0.0 | 0 | 0.4 | 1 | |
| 50–59 | 250 | 6.8 | 17 | 1.6 | b0.0 | 4 | 4.4 | 11 | 25.2 | 63 | 0.0 | 0 | 0.4 | 1 | ||
| Total | 500 | 6.6 | 5.4 | 27 | 1.8 | b0.0 | 9 | 3.8 | 19 | 22.8 | 114 | 0.0 | 0 | 0.4 | 2 | |
| FR | 40–49 | 299 | 9.4 | 28 | 4.4 | 3.2 | 13 | 2.0 | 6 | 23.1 | 69 | 0.0 | 0 | 2.7 | 8 | |
| 50–59 | 298 | 10.4 | 31 | 8.1 | 8.0 | 24 | 10.7 | 32 | 48.0 | 143 | 0.0 | 0 | 3.4 | 10 | ||
| Total | 597 | 4.0 | 9.9 | 59 | 6.2 | 5.6 | 37 | 6.4 | 38 | 35.5 | 212 | 0.0 | 0 | 3.0 | 18 | |
| GR | 40–49 | 250 | 6.0 | 15 | 4.8 | 3.8 | 12 | 26.8 | 67 | 72.4 | 181 | 0.0 | 0 | 11.6 | 29 | |
| 50–59 | 250 | 5.2 | 13 | 3.2 | 1.7 | 8 | 59.6 | 149 | 91.6 | 229 | 4.8 | 12 | 31.2 | 78 | ||
| Total | 501 | 9.8 | 5.6 | 28 | 4.0 | 2.7 | 20 | 43.3 | 217 | 82.0 | 411 | 2.4 | 12 | 21.4 | 107 | |
| HU | 40–49 | 260 | 5.0 | 13 | 1.5 | b0.0 | 4 | 3.5 | 9 | 60.4 | 157 | 0.0 | 0 | 2.7 | 7 | |
| 50–59 | 273 | 4.8 | 13 | 3.7 | 2.3 | 10 | 12.5 | 34 | 68.1 | 186 | 0.0 | 0 | 2.2 | 6 | ||
| Total | 533 | 4.5 | 4.9 | 26 | 2.6 | 0.9 | 14 | 8.1 | 43 | 64.4 | 343 | 0.0 | 0 | 2.4 | 13 | |
| IE | 40–49 | 250 | 8.4 | 21 | 5.6 | 4.8 | 14 | 33.2 | 83 | 76.4 | 191 | 0.4 | 1 | 12.8 | 32 | |
| 50–59 | 249 | 10.4 | 26 | 5.6 | 4.8 | 14 | 41.8 | 104 | 77.1 | 192 | 2.0 | 5 | 21.3 | 53 | ||
| Total | 499 | 3.8 | 9.4 | 47 | 5.6 | 4.8 | 28 | 37.5 | 187 | 76.8 | 383 | 1.2 | 6 | 17.0 | 85 | |
| LV | 40–49 | 250 | 4.8 | 12 | 4.0 | 2.7 | 10 | 1.2 | 3 | 22.0 | 55 | 0.0 | 0 | 0.8 | 2 | |
| 50–59 | 250 | 9.6 | 24 | 5.2 | 4.3 | 13 | 9.2 | 23 | 44.0 | 110 | 0.0 | 0 | 3.6 | 9 | ||
| Total | 500 | 5.2 | 7.2 | 36 | 4.6 | 3.5 | 23 | 5.2 | 26 | 33.0 | 165 | 0.0 | 0 | 2.2 | 11 | |
| LT | 40–49 | 250 | 7.2 | 18 | 4.8 | 3.8 | 12 | 2.8 | 7 | 27.6 | 69 | 0.4 | 1 | 3.6 | 9 | |
| 50–59 | 250 | 10.8 | 27 | 8.0 | 8.0 | 20 | 10.8 | 27 | 48.4 | 121 | 0.8 | 2 | 8.4 | 21 | ||
| Total | 500 | 2.8 | 9.0 | 45 | 6.4 | 5.8 | 32 | 6.8 | 34 | 38.0 | 190 | 0.6 | 3 | 6.0 | 30 | |
| NL | 40–49 | 830 | 8.6 | 71 | 4.9 | 3.9 | 41 | 12.3 | 102 | 56.5 | 469 | 0.5 | 4 | 4.6 | 38 | |
| 50–59 | 814 | 7.5 | 61 | 5.9 | 5.2 | 48 | 13.3 | 108 | 58.6 | 477 | 0.1 | 1 | 5.8 | 47 | ||
| Total | 1644 | 5.6 | 8.0 | 132 | 5.4 | 4.5 | 89 | 12.8 | 210 | 57.5 | 946 | 0.3 | 5 | 5.2 | 85 | |
| NO | 40–49 | 251 | 12.0 | 30 | 7.6 | 7.4 | 19 | 5.6 | 14 | 31.9 | 80 | 0.0 | 0 | 3.6 | 9 | |
| 50–59 | 251 | 13.1 | 33 | 11.2 | 12.1 | 28 | 8.8 | 22 | 32.7 | 82 | 0.4 | 1 | 6.8 | 17 | ||
| Total | 502 | 2.0 | 12.5 | 63 | 9.4 | 9.7 | 47 | 7.2 | 36 | 32.3 | 162 | 0.2 | 1 | 5.2 | 26 | |
| PT | 40–49 | 250 | 6.0 | 15 | 4.0 | 2.7 | 10 | 7.6 | 19 | 42.4 | 106 | 0.0 | 0 | 0.4 | 1 | |
| 50–59 | 250 | 6.4 | 16 | 4.4 | 3.2 | 11 | 10.0 | 25 | 41.6 | 104 | 0.0 | 0 | 0.4 | 1 | ||
| Total | 500 | 8.8 | 6.2 | 31 | 4.2 | 2.9 | 21 | 8.8 | 44 | 42.0 | 210 | 0.0 | 0 | 0.4 | 2 | |
| RO | 40–49 | 252 | 7.1 | 18 | 4.0 | 2.7 | 10 | 25.8 | 65 | 77.4 | 195 | 0.0 | 0 | 4.0 | 10 | |
| 50–59 | 252 | 11.1 | 28 | 4.0 | 2.7 | 10 | 25.0 | 63 | 74.2 | 187 | 0.4 | 1 | 12.3 | 31 | ||
| Total | 504 | 5.2 | 9.1 | 46 | 4.0 | 2.6 | 20 | 25.4 | 128 | 75.8 | 382 | 0.2 | 1 | 8.1 | 41 | |
| SK | 40–49 | 250 | 6.0 | 15 | 7.2 | 6.9 | 18 | 5.2 | 13 | 64.4 | 161 | 0.0 | 0 | 2.0 | 5 | |
| 50–59 | 250 | 5.6 | 14 | 4.8 | 3.8 | 12 | 6.8 | 17 | 71.2 | 178 | 0.4 | 1 | 1.2 | 3 | ||
| Total | 500 | 4.8 | 5.8 | 29 | 6.0 | 5.3 | 30 | 6.0 | 30 | 67.8 | 339 | 0.2 | 1 | 1.6 | 8 | |
| SI | 40–49 | 263 | 7.2 | 19 | 4.6 | 3.5 | 12 | 1.9 | 5 | 26.6 | 70 | 0.0 | 0 | 0.4 | 1 | |
| 50–59 | 261 | 5.0 | 13 | 3.8 | 2.5 | 10 | 10.3 | 27 | 37.9 | 99 | 0.0 | 0 | 1.5 | 4 | ||
| Total | 524 | 4.4 | 6.1 | 32 | 4.2 | 2.9 | 22 | 6.1 | 32 | 32.3 | 169 | 0.0 | 0 | 1.0 | 5 | |
| SE | 40–49 | 253 | 9.5 | 24 | 6.3 | 5.8 | 16 | 11.5 | 29 | 58.5 | 148 | 0.0 | 0 | 5.5 | 14 | |
| 50–59 | 251 | 6.0 | 15 | 4.0 | 2.7 | 10 | 21.1 | 53 | 62.2 | 156 | 0.4 | 1 | 6.4 | 16 | ||
| Total | 504 | 3.2 | 7.7 | 39 | 5.2 | 4.2 | 26 | 16.3 | 82 | 60.3 | 304 | 0.2 | 1 | 6.0 | 30 | |
| UK | 40–49 | 250 | 4.0 | 10 | 5.2 | 4.3 | 13 | 24.8 | 62 | 71.6 | 179 | 1.2 | 3 | 7.6 | 19 | |
| 50–59 | 249 | 5.6 | 14 | 4.4 | 3.3 | 11 | 35.7 | 89 | 79.1 | 197 | 0.4 | 1 | 8.8 | 22 | ||
| Total | 499 | 8.6 | 4.8 | 24 | 4.8 | 3.7 | 24 | 30.3 | 151 | 75.4 | 376 | 0.8 | 4 | 8.2 | 41 | |
aIgG anti-PT percentage (%) ≥100 IU/mL corrected for assay sensitivity (Se = 78%) and specificity (Sp = 98%).
bCalculated negative IgG anti-PT percentage (%) ≥100 IU/mL changed to 0.0%.
Abbreviations of all participating countries are listed in Table 1.